IP Library Granted Patent US 10,175,239
Granted Patent B2
US 10,175,239 · App. 15/504,633 · Granted Jan 8, 2019

Beta lactamase as biomarker for the specific detection of tuberculosis-complex bacteria

Inventors: Jeffrey D. Cirillo (College Station, TX); Michael T. Norman (Temple, TX)
Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
G01N33/573C07K16/1289C07K16/40C12N9/86C12Q1/04C12Q1/689C12Y305/02006G01N33/5695G01N33/6854C07K2317/33G01N2333/35G01N2333/986G01N2469/10G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,175,239
App. No.
15/504,633
Granted
Jan 8, 2019
Kind
B2
Abstract

The present disclosure provides methods, reagents, systems, and devices that target β lactamase as a biomarker for the sensitive and specific detection of tuberculosis-complex bacteria. Specifically, the present disclosure relates to methods and compositions for the detection of specific β-lactamase protein and nucleic acid sequences to indicate the presence of tuberculosis-complex bacteria.

Claims (9)

1. A method of detecting the presence of tuberculosis-complex bacteria in a biological sample, the method comprising contacting the sample with an antibody or antibody fragment that specifically binds to a β-lactamase (BlaC) of a tuberculosis-complex bacteria, and detecting the formation of a complex between the BlaC and the antibody or antibody fragment, wherein the formation of a complex is indicative of the presence of tuberculosis-complex bacteria in the sample.

2. The method of claim 1 , wherein the antibody or antibody fragment specifically binds to BlaC with an amino acid sequence set forth in SEQ ID NO:2.

3. The method of claim 1 , wherein the antibody or antibody fragment comprises a detectable label.

4. The method of claim 1 , wherein the formation of a complex between the BlaC and the antibody or antibody fragment is detected by further contacting the complex with an affinity reagent that contains a detectable label and that specifically binds to the complex.

5. The method of claim 1 , further comprising contacting the biological sample with an immobilized BlaC protein or immobilized antibody or antibody fragment.

6. The method of claim 1 , wherein the biological sample is obtained from a subject suspected of having tuberculosis-complex bacteria, and wherein the presence of tuberculosis-complex bacteria in the biological sample is indicative of a tuberculosis infection in the subject.

7. The method of claim 6 , wherein the subject is human.

8. The method of claim 1 , wherein the antibody is a polyclonal antibody, a monoclonal antibody, a single chain antibody, an antigen binding enzymatic digestion product of the antibody, a chimeric antibody, or a humanized antibody.

9. The method of claim 1 , wherein the tuberculosis-complex bacteria are from one or more of the species selected from the group consisting of: Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium bovis - Bacillus Calmette-Guérin (BCG), Mycobacterium africanum, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii , and Mycobacterium mungi.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: CIRILLO, JEFFREY D.
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 044917/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: NORMAN, MICHAEL T.
To: GLOBAL BIODIAGNOSTICS CORP.
Reel/Frame 044917/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: GLOBAL BIODIAGNOSTICS CORP.
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 044917/0990 →
Continuity (3)
Provisional Application 62038736 · Aug 18, 2014
Provisional Application 62134332 · Mar 17, 2015
Related Publication 20170350890A1 · Dec 7, 2017
Cited By (2)
US 12,195,755 US 12,509,559